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Summary
 
Epithelial cells of the alimentary tract play a central role in mucosal immunophysiology. Patho-
gens and/or agonists that interact with mucosal surfaces often elicit epithelial responses that up-
regulate inflammation. Therefore, it was of interest to explore potential epithelial targeted anti-
inflammatory signals. Here we identified and sequenced a human enterocyte lipoxin (LX) A
 
4
 
[5(S),6(R),15(S)-trihydroxy-7,9,13-
 
trans
 
-11-
 
cis
 
 eicosatetraenoic acid] receptor, and demon-
strate that transcription of this receptor was controlled by cytokines, of which lymphocyte-
derived interleukin (IL)-13 and interferon 
 
g
 
 were the most potent. When lipoxins and LXA
 
4
 
stable analogs were evaluated for enterocyte functional as well as immune responses, lipoxins
sharply inhibited TNF-
 
a
 
–induced IL-8 release but did not alter either barrier function or ago-
nist-stimulated chloride secretion. 15
 
R/S
 
-methyl-LXA
 
4
 
 and 16-phenoxy-LXA
 
4
 
 each attenu-
ated (IC
 
50
 
 
 
z
 
10 nM) IL-8 release. Cyclooxygenase (COX) II is emerging as an important com-
ponent in wound healing and proliferation in intestinal epithelia and when acetylated by
acetylsalicylic acid (aspirin) initiates the biosynthesis of a LXA
 
4
 
 receptor ligand. We therefore
determined whether colonic cell lines (HT-29 Cl.19A, Caco-2, or T84) express the COX II
isozyme. Results for RT-PCR and Western blot analysis showed that COX I as well as an IL-
1
 
b
 
– and TNF-
 
a
 
–inducible COX II are expressed in HT-29 Cl.19A. In addition, aspirin-
treated enterocytes generated 15R-HETE, a precursor of 15-epi-LXA
 
4
 
 biosynthesis, whose
potent bioactions were mimicked by the stable analog 15
 
R/S
 
-methyl-LXA
 
4
 
. Taken together,
these results identify an endogenous pathway for downregulating mucosal inflammatory events
and suggest a potential therapeutic benefit for LXA
 
4
 
 stable analogs.
 
E
 
pithelial cells that line the alimentary tract serve as the
barrier separating the lumen from underlying tissues. It
is now apparent that enterocytes play a critical role in mu-
cosal immunophysiology that, in part, consists of a para-
crine network between enterocytes and the underlying
immune and inflammatory cells (1–5). This view is sup-
ported by the observation that the release of lymphocyte-
derived mediators alters enterocyte phenotype and function
as evidenced by the impact of IFN-
 
g
 
 on human entero-
cytes in vitro. IFN-
 
g
 
 attenuates barrier function and ago-
nist-stimulated chloride secretion as well as induces expres-
sion of MHC class II molecules for enterocyte immune
accessory functions (1, 6). In addition, lymphocytes can
convert enterocytes into M cells that transport antigen to
underlying immune cells, an action constituting an impor-
tant component of oral vaccination and immunization (4).
Enterocytes can contribute to the regulation of mucosal
immune responses by releasing cytokines and chemokines
that can in turn activate and recruit inflammatory as well
as immune cells to the mucosa. For example, TNF-
 
a
 
 or
pathogens can induce release of a potent leukocyte chemoat-
tractant, namely IL-8, by intestinal epithelial cell lines as
well as freshly isolated human colon enterocytes (7, 8).
Only pathways that upregulate the inflammatory/immune
response are recognized to date in agonist- or pathogen-
stimulated enterocytes (for review see reference 1).
It is therefore of interest to elucidate regulatory signals
that could attenuate mucosal immune functions. In this
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regard, endogenously generated lipoxin A
 
4
 
 (LXA
 
4
 
: 5(S),
6(R),15(S)-trihydroxy-7,9,13-
 
trans
 
-11-
 
cis
 
 eicosatetraenoic
acid)
 
1
 
 is of interest because it inhibits the action of proin-
flammatory stimuli both in vitro and in vivo (for review see
reference 9). LXA
 
4
 
 is a potent inhibitor of both neutrophil
adhesion and transmigration across endothelia or epithelia.
It is then of special interest that acetylsalicylic acid (aspirin)
triggers the biosynthesis of a recently discovered novel
pathway that leads to transcellular production of 15-epi-
LXA
 
4
 
, since enterocytes are probably among the first cell
types to encounter orally administered aspirin. This trans-
cellular route involves acetylation of cyclooxygenase
(COX) II by aspirin in both human endothelia and lung
epithelia (10, 11) and formation of 15-epi-LXA
 
4
 
 by neigh-
boring neutrophils. The C-15 alcohol of 15-epi-LXA
 
4
 
 is in
the rectus (R) configuration, rather than sinister (S) as in na-
tive LXA
 
4
 
. This switch in chirality enhances its bioactivity as
well as resistance to metabolic inactivation (9). The inhibi-
tory actions of LXA
 
4
 
 and the aspirin-triggered 15-epi-LXA
 
4
 
provided an intriguing opportunity to develop stable LXA
 
4
 
and 15-epi-LXA
 
4
 
 analogs. These analogs were recently
evaluated in a mouse in vivo inflammation model and proved
to be topically active, and also more potent inhibitors of
LTB
 
4
 
-initiated inflammation than was the well-known an-
tiinflammatory steroid, namely dexamethasone (12).
The bioactions of LXA
 
4
 
, 15-epi LXA
 
4
 
, and LXA
 
4
 
 stable
analogs are transduced by a high affinity myeloid G pro-
tein–coupled receptor that has been sequenced and cloned
for both mouse (12) and human leukocytes (13, 14). In ad-
dition, LXA
 
4
 
 actions with vascular endothelial and mesan-
gial cells are mediated via a distinct nonmyeloid receptor
that remains to be cloned (9). In the gastrointestinal tract,
COX II upregulation is associated with human colorectal
adenocarcinomas (15, and see reference 16 for review),
mucosal lesions (17), colitis (18), and acute pathogen inva-
sion (19). This localization of the enzyme and its regulation
can provide a strategic in vivo milieu “primed” for the bio-
synthesis of aspirin-triggered 15-epi-lipoxins.
Since enterocytes are in close proximity to cell types of
the immune system and are among the first cell types to en-
counter orally administered aspirin, the actions of 15-epi-
LXA
 
4
 
 on these cells are of potential interest. Also, in view
of cytokine-mediated upregulation of epithelial immune
function and its associated increase in IL-8 release in hu-
man ulcerative colitis (20) and Crohn’s colitis (21), as well
as increased levels of TNF-
 
a
 
 (22), it was of interest to elu-
cidate endogenous signals that might attenuate mucosal in-
flammatory responses. To this end, we identified the first
nonmyeloid LXA
 
4
 
R in human enterocytes, and we dem-
onstrate here that expression of this receptor is regulated by
cytokines and that stable analogs of LXA
 
4
 
 and aspirin-trig-
gered 15-epi-LXA
 
4
 
 are potent inhibitors of agonist-induced
IL-8 secretion by enterocytes. These results provide the
first evidence that LXA
 
4
 
R gene expression is associated
with immune functions of human enterocytes.
 
Materials and Methods
 
Materials.
 
Synthetic LXA
 
4
 
, LXB
 
4
 
 [5(S),14(R),15(S)-trihydroxy-
6,10,12-trans-8-cis-eicosatetraenoic acid], LTD
 
4
 
 [5(S)-hydroxy-
(6R)-S-cysteinyl-glycyl-7,9-trans-11,14-eicosatetraenoic acid], 5-
HETE (15-hydroxy-5,8,11-
 
cis
 
-13-
 
trans
 
-eicosatetraenoic acid), 12-
HETE, and 15-HETE were purchased from Cascade Biochem
Limited (Reading, Berkshire, UK). Arachidonic acid was obtained
from Cayman Chemical Company (Ann Arbor, MI). Acetylsali-
cylic acid (aspirin) was purchased from Spectrum Chemical Mfg.
Corp. (Gardena, CA). 16-phenoxy-LXA
 
4
 
-methyl ester and 15(
 
R/
S
 
)-methyl LXA
 
4
 
-methyl ester were prepared by total synthesis for
the present experiments by Dr. Nicos Petasis and colleagues
(University of Southern California, Los Angeles, CA) as in refer-
ence 23. LXA
 
4
 
 analogs used in these experiments were carboxy
methyl esters. Recombinant human (r) IL-8, rIL-1
 
b
 
, rIL-4, rIL-6,
rIL-13, and rIFN-
 
g
 
 were purchased from R&D Systems (Minne-
apolis, MN). Dulbecco’s PBS (DPBS), DMEM, and Ham’s F-12
were obtained from Bio Whittaker (Walkersville, MD) and
HBSS was from GIBCO BRL (Gaithersburg, MD). First strand
cDNA synthesis kit was purchased from Promega (Madison, WI),
and all other molecular biology reagents were obtained from
Boehringer Mannheim Corp. (Indianapolis, IN). Human colonic
epithelial cell lines (Caco-2 and T84) and alveolar epithelial cells
(A549) were purchased from the American Type Culture Collec-
tion (Rockville, MD), and HT-29 Cl.19A were generously pro-
vided by Dr. Laboisse (Universite de Nantes, Nantes, France).
Oligonucleotide primers were purchased from Integrated DNA
Technologies (Coralville, IA). Sep-Pak C
 
18
 
 cartridges were ob-
tained from Alltech (Deerfield, IL). Methyl formate was pur-
chased from Eastman Kodak Co. (Rochester, NY). Hexane and
all HPLC solvents were purchased from J.T. Baker (Phillipsburg,
NJ). Calcium ionophore (A23187) and all other reagents were
obtained from Sigma Chemical Co. (St. Louis, MO).
 
Epithelial Cell Lines and Culture.
 
Human colonic adenocarci-
noma cell lines were grown and passaged in culture conditions as
previously described for T84 (24), Caco-2 (25), and HT-29
Cl.19A (26) at 37
 
8
 
C in an atmosphere of 5% CO
 
2
 
. In brief, T84
cells were propagated in 1:1 mixture of DMEM and Ham’s F-12
medium supplemented with 14 mM NaHCO
 
3
 
, 40 mg/liter peni-
cillin, 9 mg/liter streptomycin, 8 mg/liter ampicillin, 5% new-
born calf serum, and 15 mM Na
 
1
 
 Hepes buffer, pH 7.5. HT-29
Cl.19A and Caco-2 were propagated in DMEM containing a
standard (4.5 gram/liter) glucose concentration and supplemented
with 14 mM NaHCO
 
3
 
, 40 mg/liter penicillin, 9 mg/liter strepto-
mycin, 8 mg/liter ampicillin, 10% fetal bovine serum, and 15 mM
Hepes buffer, pH 7.5. The human lung adenocarcinoma cell line
A549 was grown and passaged as in reference 11.
Polarized colonic epithelial cells were split near confluency by
incubating cells with 0.1% trypsin and 0.9 mM EDTA in Ca
 
2
 
1
 
-
and Mg
 
2
 
1
 
-free DPBS for 5–20 min. Cells were diluted in media
alone or in media containing IL-1
 
b
 
 (1 ng/ml), IL-4 (10 ng/ml),
IL-6 (1,000 U/ml), IL-13 (10 ng/ml), IFN-
 
g
 
 
 
(1,000 U/ml), and
LPS (500 ng/ml), and then were incubated for 24 and/or 48 h.
Cytokine selection and concentrations selected for evaluation in
 
1
 
Abbreviations used in this paper:
 
 15-epi-LXA
 
4
 
, 5(S),6(R),15(R)-trihy-
droxy-7,9,13-
 
trans
 
-11-
 
cis
 
 eicosatetraenoic acid; 15 (
 
R/S
 
)-methyl LXA
 
4
 
,
5(S),6(R), 15(
 
R/S
 
)-trihydroxy-15-methyl-7,9,13-
 
trans
 
-11-
 
cis
 
-eicosatet-
raenoic acid; 16-phenoxy-LXA
 
4
 
, 16-phenoxy-17,18,19,20-tetranor-LXA
 
4
 
;
aspirin, acetylsalicylic acid; COX, cyclooxygenase (PGHS); 15-HETE,
15-hydroxy-5,8,11-
 
cis
 
-13-
 
trans
 
-eicosatetraenoic acid; LO, lipoxygenase;
LXA
 
4
 
, 5(S),6(R),15(S)-trihydroxy-7,9,13-
 
trans
 
-11-
 
cis
 
 eicosatetraenoic
acid; LXA
 
4
 
R, lipoxin A
 
4
 
 receptor; RP-HPLC, reverse phase-HPLC. 
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our experiments were based on results from published studies us-
ing epithelial cells (6, 11, 27). In experiments analyzing entero-
cyte barrier function, chloride secretion, and IL-8 release, polar-
ized monolayers of T84 were grown on collagen-coated permeable
supports and maintained until steady-state transepithelial resis-
tance (i.e., 
 
.
 
600 
 
V 3 
 
cm
 
2
 
) was achieved, as previously detailed
in reference 24.
 
Reverse Transcription and PCR.
 
Total RNA from colonic
(T84, Caco-2, HT-29 Cl.19A) or alveolar epithelial cells (A549),
which were exposed to either IL-1
 
b
 
 (1 ng/ml) or media alone for
24 h, was extracted with TriZol reagent (GIBCO BRL) accord-
ing to the manufacturer’s instructions. RNA was further purified
by chloroform/phenol/isoamyl (24:25:1) extraction and cDNA
was produced by reverse transcription. Oligonucleotide sense and
antisense primers were constructed from published sequences of
COX II (28), myeloid 15-lipoxygenase (LO; reference 29), 12-
LO (30), and 5-LO (31). Primers for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were used as internal controls, as de-
scribed in reference 11. Amplification protocols for COX II and
GAPDH consisted of 25 repetitive cycles of denaturing at 94
 
8
 
C
(1 min), annealing at 58
 
8
 
C (2 min), and extension at 72
 
8
 
C (3
min). 5-, 12- and 15-LO were amplified by 35 repetitive cycles
of denaturing at 94
 
8
 
C (1 min), annealing at 55
 
8
 
C (2 min), and ex-
tension at 72
 
8
 
C (2.5 min). Amplified cDNA was separated by
agarose gel electrophoresis and visualized with ethidium bromide.
 
Identification and cDNA Cloning of the Intestinal Epithelial LXA
 
4
 
R.
 
Total RNA was isolated from T84, HT-29 Cl.19A, Caco-2, or
A549 as described above, and 0.5 
 
mg of RNA was reverse tran-
scribed. Oligonucleotide primers, sense primer 59-CACCAGGT-
GCTGCTGGCAAG-39 and antisense primer 59-AATATCCC-
TGACCCCATCCTCA-39, were designed to amplify the published
human myeloid LXA4R coding region (z1.1 kb; reference 12).
Amplification protocols, using the high fidelity polymerase PCR
system Expand (Boehringer Mannheim Corp.), consisted of 35
repetitive cycles of denaturing at 948C (30 s), annealing at 648C
(45 s), and extension at 728C (80 s). In parallel analysis, oligonucle-
otide primers designed for the recently sequenced myeloid LTB4
receptor (32), sense primer 59-GGCAAGCTTATGAACACT
ACATCTTCT-39 and antisense primer 59-GGCAGGACCT-
CTAGTTCAGTTCGTTTA-39, were used to amplify the LTB4
receptor coding region (z1.1 kb). The amplification protocol,
using vent (New England Biolabs, Beverly, MA) as the poly-
merase, consisted of 35 repetitive cycles of denaturing at 988C (60
s), annealing at 608C (60 s), and extension at 728C (70 s). PCR
analysis of LXA4R demonstrated a single PCR product from T84
cDNA with an apparent size of z1.1 kb, which was subcloned
into pBluescript KS(1), and three independent clones were iso-
lated and selected for analysis at the Children’s Hospital sequenc-
ing facility (Boston, MA). The following oligonucleotide primers
were used to sequence the 1,053-bp coding region of the human
enterocyte LXA4R: nucleotides 0–264 [pBluescript KS (1) re-
verse primer] and 884–1053 (M13-20 sense primer); nucleotides
210–631 (59-ATCTGTTACCTGAACCTGGC-39) and 514–914
(59-GTCTCTCTCGGAAGTCTTGG-39); and nucleotides 477–
907 (59-TTGCTCTAGTCCTTACCTTGC-39) and 461–818
(59-GATGTCAATGATTTTGTACTTGC-39).
Northern Blot Analysis of Enterocyte LXA4R Messenger RNA.
Confluent T84 cells (resistance .600 V 3 cm2) were exposed to
media alone or selected cytokines (IL-1b, IL-4, IL-6, IL-13,
IFN-g, or LPS) for 24 or 48 h. PolyA1 RNA was directly iso-
lated from cells using the FastTrackÒ 2.0 messenger (m)RNA iso-
lation system (Invitrogen, San Diego, CA) according to the man-
ufacturer’s instructions. mRNA (3 mg) was purified by gel
electrophoresis in 1% agarose gel containing 1.9% formaldehyde
and was then blotted to nylon membrane. The cDNA of the human
leukocyte LXA4R coding region was labeled with a-[32P]dCTP
using Oligolabeling kit (Pharmacia Biotech AB, Piscataway, NJ)
and hybridization was performed in 1% BSA, 7% SDS, 0.5 M
phosphate buffer (pH 6.8), and 1 mM EDTA as in reference 33.
Filters were washed in buffer A (0.5% BSA, 5% SDS, 40 mM
phosphate buffer [pH 6.8], and 1 mM EDTA) twice for 20 min at
658C, and then in buffer B (1% SDS, 40 mM phosphate buffer
[pH 6.8], and 1 mM EDTA) four times for 20 min at 658C. After
quantitation using a PhosphorImager (Molecular Dynamics, San
Lorenzo, CA), the filter was washed in 50% formamide to re-
move the LXA4R probe and was reprobed with a-32P-labeled
actin cDNA (Clontech, Palo Alto, CA). Northern hybridization
was quantitated by PhosphorImager using Image-Quant program-
ming (Molecular Dynamics), and LXA4R mRNA was normalized
to actin mRNA levels in each treatment condition.
Barrier Function and Chloride Secretion in Human Enterocytes.
Polarized monolayers of T84 (resistance .600 V 3 cm2) were
grown on matrix-coated permeable supports that divided the
monolayer into an upper (apical) and lower (basolateral) compart-
ment. Apical and basolateral epithelial compartments were ex-
posed to media alone, LXA4, or LXB4 at indicated concentrations
for 24 or 48 h. After 24 h, complete media was replaced and
eicosanoid treatment was repeated for both apical and basolateral
compartments. The impact of LXA4 analogs that resist metabolic
inactivation was evaluated by exposing apical and basolateral
compartments to 15R/S-methyl-LXA4 or 16-phenoxy-LXA4 (1
nM–1 mM) for 30 min to 24 h. After exposure to lipoxin, LXA4
analog, or vehicle, cells were washed with HBSS and all subse-
quent measurements were made in a 378C environment. Entero-
cytes were stimulated with forskolin (10 mM) for 10 min to stim-
ulate chloride secretion. Short circuit currents, transepithelial
potentials, and resistances were measured with a voltage clamp
(Iowa Dual Voltage Clamps, Bioengineering, University of Iowa,
Iowa City, IA) interfaced with an equilibrated pair of calomel
electrodes and a pair of Ag–AgCl electrodes as in reference 24.
TNF-a–induced IL-8 Release by Human Enterocytes. Polarized T84
grown on matrix-coated permeable supports were washed three
times with HBSS and the basolateral (300 ml) and apical (100 ml)
compartments were exposed to HBSS containing either LXA4,
15R/S-methyl-LXA4, or 16-phenoxy-LXA4 at indicated concen-
trations, or vehicle alone (0.1% EtOH). After incubation (30 min,
378C), human recombinant TNF-a (Endogen, Inc., Woburn,
MA) was added at a 1:100 (vol/vol) ratio to both apical and baso-
lateral compartments. TNF-a was tested in the concentration
range of 0.02–0.5 nM to evaluate the impact of LXA4 and LXA4
analogs on the distinct signal transduction pathways of the TNF
receptors CD120a (Kd 0.5 nM) and CD120b (Kd 0.1 nM) (34–36).
After a 5-h exposure, IL-8 release was measured in the basolateral
compartment by ELISA, which has been previously identified as
the site of chemokine release in polarized human enterocytes (7,
8). IL-8 release was measured by ELISA as in reference 8. In
brief, 96-well plates (Libro/Titretek, ICN Biomedicals, Aurora,
OH) were coated overnight with goat a-human IL-8 antibody
(R&D Systems). Rabbit a-human IL-8 (Endogen, Inc.) was used
as the detection antibody and peroxidase conjugated rabbit a-goat
IgG was used as the reporting antibody. After addition of the sub-
strate, the plates were read at a wavelength of 650 nm.
Western Blot Analysis of COX I and II Proteins in Human Entero-
cytes. Subconfluent HT-29 Cl.19A were lifted with trypsin/
EDTA and resuspended in media containing IL-1b (1 ng/ml)
and/or TNF-a (50–100 ng/ml) or media alone and incubated for1288 Enterocyte IL-8 Is Inhibited by LXA4 Receptor Activation
24 or 48 h. Enterocytes were washed twice in DPBS, resus-
pended, and incubated in lysis buffer for 10 min (50 mM Tris-
HCl, pH 7.5; 10 mM EDTA; 1% Triton X-100; 1 mM PMSF;
200 mM leupeptin; and 50 mM pepstatin A) and sonicated (three
10-s bursts) with a Sonic Dismembrator (Model 60; Fisher Scien-
tific Co., Pittsburgh, PA). Protein concentrations in the cell ex-
tract were determined using a Bio-Rad DC Protein Assay (Bio-
Rad Laboratories, Hercules, CA). Cell extracts were boiled for 5
min in gel-loading buffer and equal amounts of protein were sep-
arated by SDS-PAGE according to Laemmli’s method. Proteins
were transferred to a polyvinylidene difluoride microporous
membrane by electroblotting. The membrane was blocked in 1%
blocking reagent (Boehringer Mannheim Corp.) in TBST (Tris-
buffered saline containing 0.1% vol/vol Tween 20 [0.9% NaCl
and 0.1% Tween 20 in 20 mM Tris-HCl, pH 7.4]) and probed (1 h,
room temperature) with either an anti-human COX II polyclonal
antibody or polyclonal anti-COX I peptide antibody (Oxford
Biomedical Research, Oxford, MI). Membranes were washed three
times in TBST followed by an incubation with horseradish per-
oxidase–linked goat anti–rabbit IgG (1:10,000 dilution) for 30 min.
Immunoreactive bands were developed with chemiluminescence
substrates (Boehringer Mannheim) and visualized by exposure to
x ray film. COX protein levels were quantitated by densitometry.
Analysis of Mono-HETE Generation by Human Enterocytes.
Confluent HT-29 Cl.19A cells that were exposed for 24 h to ei-
ther media alone or to both IL-1b (1 ng/ml) and TNF-a (50 ng/ml)
were washed twice and suspended in DPBS. Enterocytes were
incubated with either vehicle alone or aspirin (300 mM). After a
20 min incubation, cells were permeabilized by two rapid freeze–
thaw cycles and stimulated with 20 mM of arachidonic acid for 30
min as in reference 11. Incubations were terminated with the ad-
dition of 2 vol of cold MeOH and 200 ng of PGB2 were added as
an internal standard.
Eicosanoids were extracted using Sep-Pak C18 cartridges as in
reference 37. Materials eluting in the methyl formate fraction
were taken to dryness using a stream of nitrogen and suspended in
HPLC mobile phase. The reverse phase (RP)-HPLC system con-
sisted of a dual pump gradient (LKB, Bromma, Sweden), a diode
array detector (Hewlett-Packard 1040M series II; Hewlett Pack-
ard, San Fernando, CA), and HPLC3D ChemStation software.
Collected UV data were recalled at 234 nm for detecting the
presence of conjugated dienes (mono-HETEs). All spectra were
acquired using step 5 4 nm and bandwidth 5 10 nm, with a
sampling interval of 0.96 s. Monohydroxy eicosanoids (i.e., 5-,
12-, and 15-HETE) from HT-29 Cl.19A cells were chromato-
graphed using an Ultrasphere-ODS (5 mm, 4.6 mm 3 25 cm)
column (Beckman Instruments, Fullerton, CA) with MeOH/
H2O/acetic acid (65:35:0.01; vol/vol/vol) as phase 1 (0–20 min),
and a linear gradient with MeOH/acetic acid (99.99:0.01; vol/
vol) as phase 2 (20–45 min) at a flow rate of 1.0 ml/min. The area
beneath the peaks of eluting compounds was corrected for recov-
ery of PGB2 (used as internal standard), integrated using Chem-
Station software and quantitated by direct comparison to peak ar-
eas of their corresponding authentic standards in this system.
Statistical Analysis. Unless otherwise indicated, all values are rep-
resented as mean values 6 SEM. Results were analyzed using Stu-
dent’s t test. Differences were considered significant at the P ,0.05
level.
Results
Cloning of the Human Enterocyte LXA4R and Its Regulation
by Cytokines. To elucidate potential bioactions of LXA4
and 15-epi-LXA4 with human enterocytes, we first sought
to determine whether LXA4Rs are present in human co-
lonic epithelia using established model cell lines. Reverse
transcription (RT)-PCR analysis of enterocyte-derived cDNA
demonstrated a single band with the expected size of z0.7
kb present in T84, HT-29 Cl.19A, and Caco-2. It is of in-
terest to note that another epithelial cell line from the air-
way, A549, did not show appreciable levels of the LXA4R
cDNA (data not shown). To determine the sequence ho-
mology of the human enterocyte LXA4R and those of the
human and mouse myeloid receptors (9, 12), specific LXA4
primers were designed to amplify the complete coding re-
gion (z1.1 kb; see Materials and Methods). T84 cells gave
an z1.1 kb PCR product that was isolated, cloned, and se-
quenced. Three independent clones contained a 1,053-bp
cDNA that was identical to the human myeloid LXA4R.
Of interest, RT-PCR analysis did not provide evidence for
expression of the recently identified human myeloid LTB4
receptor in these particular epithelial cell lines. These find-
ings clearly demonstrated that the LXA4R is not only ex-
pressed in enterocytes but that it is conserved in both hu-
man leukocytes and enterocytes. The cDNA sequence of
the human enterocyte LXA4R is available from EMBL/
GenBank/DDBJ under accession number AF054013.
Selected cytokines were recently found to be modulators
of phenotype and enterocyte function (6, 27). To evaluate
whether LXA4R expression was altered by these cytokines,
Northern blot analysis of poly1 RNA was used to monitor
LXA4R transcription in T84 cells. Cytokines for which en-
terocytes bear functional receptors were chosen for evalua-
Figure 1. Cytokines regulate epithelial LXA4R expression. Northern
blot analysis of LXA4R mRNA levels in human enterocytes (T84) ex-
posed to cytokines or buffer alone (inset). T84 were exposed to either IL-1b
(1 ng/ml), IL-4 (10 ng/ml), IL-6 (1,000 U/ml), IL-13 (10 ng/ml), IFN-g
(1,000 U/ml), LPS (500 ng/ml), or buffer alone for 24 (j) or 48 h (u).
RNA was isolated and 3 mg of poly1RNA was separated by gel electro-
phoresis, and then filters were washed and hybridized as described in Ma-
terials and Methods. LXA4R mRNA was quantitated by a PhosphorIm-
ager and normalized to corresponding actin mRNA for each treatment
protocol. Changes in receptor mRNA levels are expressed as fold increase
compared with T84 cells that were exposed to media alone.1289 Gronert et al.
tion (i.e., see Fig. 1) (6, 27). After 24 h, exposure to these
cytokines increased LXA4R mRNA levels compared with
those of cells that were exposed to media alone (Fig. 1).
Among the panel of cytokines evaluated, IL-1b and LPS
were the least potent cytokines, inducing a 1.8-fold in-
crease in LXA4R mRNA, whereas exposure to either IL-4
or IL-6 increased receptor message levels by z3-fold. The
most potent cytokines proved to be IFN-g and IL-13,
which increased LXA4R mRNA by z6.8- and 8.6-fold,
respectively. This pattern of cytokine selective upregulation
of LXA4R transcription was also observed for the 48-h in-
terval. LXA4R mRNA levels increased in each experimen-
tal group from 24 to 48 h compared with those of the con-
trol group in which message levels remained unchanged.
After 48 h of exposure, IL-1b and IL-4 increased LXA4R
message levels by a total of z4.0- to 4.5-fold, whereas IL-6
gave an z6.6-fold and LPS an z7.3-fold increase. The
most potent of the cytokines examined proved to be IL-13
and IFN-g, as they increased LXA4R mRNA by 8.4- and
17.3-fold in 48 h when compared with the parallel con-
trols. Similar patterns of selective regulation of the receptor
message levels by these cytokines were also observed using
RT-PCR analysis of total RNA from T84 (data not
shown). Together these results indicate that IL-13 and
IFN-g each selectively increase LXA4R mRNA levels.
Lipoxins Do Not Modulate Epithelial Barrier Function or For-
skolin-induced Chloride Secretion. Epithelial cells that line
the intestine perform a primary function as a selective bar-
rier and secretory cell (1, 26). We next examined whether
LXA4 or LXB4 could have an impact on epithelial barrier
function and/or agonist-induced chloride secretion when
compared with the established effect of IFN-g on entero-
cyte function (6). Neither LXA4 nor LXB4 altered T84
barrier function after 24 or 48 h of exposure when com-
pared with vehicle alone (data not shown; n 5 3). In addi-
tion, exposure to either LXA4 or LXB4 for 48 h did not
stimulate chloride secretion or alter agonist-activated (for-
skolin, 10 mM) chloride secretion in enterocytes when
compared with the vehicle control (data not shown; n 5
3). Essentially similar findings were observed after 24 h of
exposure to either LXA4 or LXB4. Furthermore, results ob-
tained with 15R/S-methyl-LXA4 and 16-phenoxy-LXA4
confirm these findings, since neither analog in a concentra-
tion range of 1 nM to 1 mM and an exposure of 30 min to
24 h altered these enterocyte functional responses (data not
shown; n 5 3). Together these results indicate that LXA4R-
mediated actions include neither modulation of epithelial
barrier function nor chloride secretion.
LXA4 Stable Analogs Are Potent Inhibitors of TNF-a–
induced IL-8 Secretion in Human Enterocytes. Intestinal epi-
thelia constitutively express low levels of IL-8 that can be
markedly upregulated by pathogens and proinflammatory
cytokines such as TNF-a. This increase in basolateral IL-8
secretion is held to be important in PMN recruitment to
the epithelium (7, 8). To evaluate whether LXA4 and
LXA4 stable analogs modulate IL-8 release, T84 monolay-
ers were stimulated with TNF-a, and IL-8 release was de-
termined after epithelial exposure to LXA4 and/or stable
analogs. IL-8 secretion in untreated T84 cells ranged from
less than the ELISA detection limit to z20 pg/epithelial
cell monolayer. TNF-a, in the concentration range ex-
pected to use the high affinity receptor (Kd z0.1 nM) (34),
induced epithelial IL-8 secretion that was significantly in-
hibited (P ,0.006) by both 15R/S-methyl-LXA4 and 16-
phenoxy-LXA4 (Fig. 2 A).
15R/S-methyl-LXA4 inhibition of TNF-a–induced IL-8
secretion was concentration dependent (Fig. 2 B) and max-
imal inhibition (65 6 14%) was observed at the highest
concentration tested, namely, 100 nM. 16-phenoxy-LXA4
at 100 nM proved to be even more potent, inhibiting ago-
nist-induced IL-8 secretion by 82 6 11% (Fig. 2 A). Fur-
thermore, IL-8 secretion induced by 0.02 and 0.2 nM
TNF-a was also significantly inhibited (z50%) by 15R/S-
methyl-LXA4 (data not shown; n 5 3). Native LXA4 did
not exhibit a statistically significant effect on TNF-a–induced
IL-8 (Fig. 2 A), although a trend toward suppression of
IL-8 secretion was consistently noted. It is likely that a de-
crease in LXA4 concentration during the incubation (5 h)
brought about by metabolic inactivation may explain its di-
minished action compared with its stable LXA4 analogs.
Stimulation of IL-8 secretion with higher concentrations of
TNF-a that were in the range of the low affinity TNF-a
receptor (z0.5 nM) (34) led to greater IL-8 secretion that
was not subject to inhibition by 100 nM 15R/S-methyl-
LXA4 (data not shown). These results indicate that LXA4
stable analogs are potent inhibitors of TNF-a–induced IL-8
release by intestinal epithelial cells and appear to selectively
inhibit signals transduced via the CD120b TNF receptor
(35, 36).
COX II Is Expressed in Human Colonic Cell Lines. Upregu-
lation of COX II in enterocytes, an enzymatic target for
Figure 2. LXA4 and aspirin-triggered 15-epi-LXA4 stable analogs are
potent inhibitors of TNF-a–induced IL-8 secretion in human entero-
cytes. Monolayers of T84 were grown on matrix-coated permeable sup-
ports. (A) Monolayers were treated with either LXA4 (100 nM), 15R/S-
methyl-LXA4 (100 nM), 16-phenoxy-LXA4 (100 nM), or vehicle (0.1%
EtOH) alone. (B) Monolayers were exposed to indicated concentrations
of 15R/S-methyl-LXA4. After 30 min of lipoxin exposure, enterocytes
were stimulated with TNF-a (0.1 nM). After 5 h the basolateral superna-
tants were removed and IL-8 concentration was measured by ELISA. Re-
sults are presented as percentage of inhibition of TNF-a–induced IL-8
release (z60 pg/monolayer of T84); each panel shows results from a rep-
resentative experiment consisting of three independent monolayers for
each experimental parameter. Essentially identical patterns were observed
in at least three separate experiments.1290 Enterocyte IL-8 Is Inhibited by LXA4 Receptor Activation
nonsteroidal antiinflammatory drug action, is associated with
intestinal inflammation and cell proliferation (16). To de-
termine whether human enterocytes have the enzymatic
capacity to serve as a site or donor for aspirin-triggered 15-
epi-lipoxin production, cDNA from untreated as well as
IL-1b–primed enterocyte cell lines was examined for the
presence of COX II. In addition, we evaluated the presence
of the lipoxygenases 5-LO, 12-LO, and myeloid 15-LO,
which are other components of the transcellular pathways
for LXA4 and 15-epi-LXA4 biosynthesis (for review see
reference 9). In the absence of cytokine stimulation, HT-29
Cl.19A and Caco-2, but not T84, expressed low levels of
COX II. Exposure to IL-1b enhanced COX II expression
in HT-29 Cl.19A cells, but no significant change in COX
II RNA levels was observed for Caco-2 cells. T84 cells did
not express appreciable amounts of COX II (Fig. 3). In-
deed, the level of enterocyte basal and cytokine-induced
COX II mRNA was less than that observed with the air-
way epithelial cell line A549 (Fig. 3). It is of interest to
note that each of these colonic epithelial cell lines (HT-29
Cl.19A, Caco-2, and T84) expressed 5-LO mRNA to
some extent. In contrast, these enterocyte cell lines ex-
pressed neither 12-LO nor 15-LO RNA (data not shown).
These findings indicate that human enterocytes (HT-29
Cl.19A and Caco-2) exposed to cytokines have the enzy-
matic capacity to generate COX II–derived eicosanoids.
Transient and Cytokine-specific Induction of COX II in Human
Enterocytes. Do changes in COX II mRNA translate to
protein levels and active enzyme in cytokine-primed en-
terocytes? To achieve high levels of COX II expression,
HT-29 Cl.19A were treated with TNF-a, a cytokine that
also induces COX II in a variety of cell types (1), or were
treated in combination with IL-1b. COX II protein levels
were quantitated and compared with COX I by Western
Figure 3. Expression of COX
II in human colonic cell lines.
Total RNA was isolated from
colonic (T84, Caco-2, and HT-
29 Cl.19A) or airway (A549) ep-
ithelial cell lines treated with ei-
ther IL-1b (1 ng/ml) or media
alone for 24 h. cDNA was ana-
lyzed by RT-PCR using specific
primers designed for human COX
II or GAPDH. PCR products
were separated on a 2% agarose gel
stained with ethidium bromide.
Similar patterns were observed in
three separate experiments.
Figure 4. IL-1b and TNF-a in-
duce COX II in human entero-
cytes. ( A ) Monolayers of HT-29
Cl.19A were exposed to IL-1b (1
ng/ml) and/or TNF-a (50 ng/ml)
for 24 (h) or 48 h (j). In select
experiments, cells were exposed to
TNF-a (100 ng/ml) and IL-1b (1
ng/ml) for 24 h (indicated by p).
Cells were homogenized and pro-
teins (30 mg/lane) were separated
on 10% polyacrylamide SDS gel,
transferred to polyvinylidene diflu-
oride microporous membrane, and
probed with a COX II–specific an-
tibody. (B) Protein (3 mg/lane)
from HT-29 Cl.19A treated with
IL-1b and/or TNF-a (50 ng/ml)
for 24 h or buffer alone for 24 (u)
or 48 h (j) was probed with a
COX I–specific antibody. Immu-
noreactive bands were quantitated
by densitometry. Identical patterns
were observed in three separate ex-
periments.1291 Gronert et al.
blot. COX II protein was not observed with the untreated
cells but was induced by both IL-1b and TNF-a after 24 h
(Fig. 4 A). TNF-a–induced COX II levels were approxi-
mately twofold higher than IL-1b–induced protein levels.
Treating cells with both cytokines gave an approximately
fourfold greater increase in COX II protein as compared
with IL-1b treatment alone. Extending exposure to these
cytokines from 24 to 48 h decreased COX II protein levels.
These findings indicate that upregulated COX II expres-
sion was transient. In addition, increasing TNF-a concen-
tration from 50 to 100 ng/ml (TNF-a 1 IL-1b exposed
for 24 h) induced COX II protein at levels that were
higher than those observed with IL-1b alone but less than
levels observed with 50 ng/ml of TNF-a alone or in com-
bination with IL-1b (24 h of exposure). These findings are
consistent with the well-characterized cytotoxic effect of
TNF-a with tumor cells such as HT-29 (38, 39).
For the purpose of direct comparison, COX I protein
levels were analyzed by Western blot. Results in Fig. 4 in-
dicate that COX I was a highly abundant protein in HT-29
Cl.19A (note that protein concentrations were reduced by
10-fold in comparison to the COX II immunoblot to
achieve visualization of immunoreactive bands). COX I
was detected in untreated cells as well as in cytokine-
primed enterocytes (Fig. 4 B). However, protein levels for
COX I were not significantly altered when these cells were
exposed to either IL-1b and/or TNF-a. Thus, in entero-
cytes, COX II levels were most effectively increased by
combined exposure to TNF-a and IL-1b. This “upregula-
tion” of COX II was transient and did not extend to COX
I, whose protein levels were not significantly altered by ex-
posure to these cytokines.
Aspirin-dependent 15-HETE Generation by Enterocytes.
Do cytokine-primed enterocytes generate 15R-HETE
when treated with aspirin? It was of interest to determine if
enterocytes (HT-29 Cl.19A) that demonstrated cytokine-
regulated COX II at both RNA and protein level (Figs. 3
and 4) also had the capacity to generate 15R-HETE when
exposed to aspirin. To this end cytokine-primed entero-
cytes were incubated with aspirin, and lipid extracts were
subjected to analysis using RP-HPLC. Aspirin-treated en-
terocytes gave a product that coeluted with authentic 15-
HETE standard and displayed a characteristic conjugated
diene UV chromophore with a maximum absorbance at
234 nm (Fig. 5, chromophore inset). 15-HETE production by
cytokine-primed enterocytes exposed to aspirin increased
by approximately threefold (Fig. 5), a finding that is consis-
tent with the notion of aspirin-dependent 15R-HETE
generation demonstrated in both endothelial cells (10) and
airway epithelial cells (11). These findings are also consis-
tent with results obtained with isolated recombinant COX
II and 15R-HETE biosynthesis (40). Of interest, RP-
HPLC profiles from permeabilized cytokine-treated en-
terocytes did not show 5-HETE generation, although we
found message for this enzyme to be present. These results
are consistent with previous studies that detected no 5-LO
activity in intact HT-29, and only after sonication were
small amounts of 5-LO products observed (41). Together,
these findings indicate that cytokine-primed enterocytes in
the presence of aspirin can generate 15R-HETE.
Discussion
Our results demonstrate that human intestinal epithelial
cells express LXA4Rs and that the stable analogs of LXA4
and aspirin-triggered 15-epi-LXA4 attenuated TNF-a–
induced IL-8 release in human enterocytes. Also, lympho-
cyte-derived cytokines exhibiting potent actions on en-
terocyte function and phenotype (6, 27) were shown here
for the first time to upregulate gene expression of this re-
ceptor. RT-PCR analysis demonstrated that the LXA4R is
expressed in established model cell lines of colonic epithe-
lial cells. These cells form functional columnar epithelia
that resemble natural in vivo crypt and brush border epi-
thelia (6, 25, 26, 42). Sequence analysis revealed that the
enterocyte LXA4R is identical to the human myeloid re-
ceptor (13, 14) and 76% homologous to the mouse leuko-
cyte receptor (12). It is therefore of interest to note that
RT-PCR analysis of RNA from other epithelial tissues in-
cluding human cornea also proved positive for the LXA4R
(data not shown), yet epithelial cells from the airway were
negative. The finding of LXA4R expression in human epi-
thelial cells suggests conserved receptor function and pro-
Figure 5. Aspirin-dependent 15-HETE generation by IL-1b– and
TNF-a–treated enterocytes. Monolayers of human enterocytes (30 3 106
HT-29 Cl.19A) were exposed to TNF-a (50 ng/ml) and IL-1b (1 ng/ml)
for 24 h. After cytokine treatment, cells were treated with aspirin (300 mM)
or vehicle alone for 20 min. Enterocytes were freeze–thaw permeabilized
and incubated with 20 mM arachidonic acid for 30 min. After extraction,
products that eluted in the methyl formate fraction were analyzed by re-
verse phase HPLC (see Materials and Methods). Inset shows the charac-
teristic mono-HETE UV chromophore of the aspirin-dependent entero-
cyte product 15-HETE. Results are representative of two separate
experiments that gave similar results.1292 Enterocyte IL-8 Is Inhibited by LXA4 Receptor Activation
vides support for the immunoregulatory role of enterocytes.
This conclusion is further supported by results from exper-
iments with human neutrophils indicating that the LXA4R
transduces signals that counterregulate proinflammatory
mediators such as LTB4 and FMLP both in vitro (9) and in
vivo (12).
The intestinal mucosa forms the most extensive barrier
separating the external environment from the internal mi-
lieu (for review see reference 1). Enterocytes are in com-
munication with the interdispersed intraepithelial lympho-
cytes and submucosal inflammatory cells to fulfill their
function as an absorptive/secretory and immune accessory
cell. In this respect, enterocytes are considered a primary
lymphoid organ and a component of the mucosal immune
system (for review see references 1 and 3). It is thus of par-
ticular interest that lymphocyte-derived cytokines upregu-
lated gene expression of the epithelial LXA4R (Fig. 1).
These cytokines initiate enterocyte immune functions that
include antigen presentation, expression of secretory com-
ponents, and transport of immunoglobulin A into the in-
testinal lumen. Cytokines associated with these phenotypic
changes, namely IL-13 (27) and IFN-g (6), were the most
potent in inducing LXA4R transcription. Of interest, IL-13
also induces 15-LO, an important enzyme in native lipoxin
biosynthesis (43).
Our results also suggest that signals transduced by the
LXA4R are associated with the immune function of human
enterocytes. Evidence to support this hypothesis is twofold.
First, LXA4, LXB4, and stable LXA4 analogs did not alter
enterocyte barrier function or cAMP-mediated chloride se-
cretion, a finding consistent with previous results showing
that exposure to LXA4 for 2 h did not impact monolayer
integrity (44). This further distinguishes lipoxin A4 from
the bioaction of prostaglandin E2, whose receptors and ac-
tion have been characterized in human enterocytes and in-
clude stimulation of cAMP-mediated chloride secretion
(45). Also, our results indicate that lipoxins do not activate
secondary mediators such as prostaglandin or arachidonic
acid release in enterocytes, since these compounds are
known to stimulate chloride secretion (45, 46). Second,
unlike the lack of impact on human enterocyte secretory
and barrier function, LXA4 and stable LXA4 analogs atten-
uated epithelial immune function, namely the inhibition of
IL-8 release.
In the mucosal milieu, enterocytes play an important
role in leukocyte recruitment by releasing basolaterally the
potent chemoattractant IL-8 (8), which is associated with
the pathogenesis of diseases such as Crohn’s (21) and ulcer-
ative colitis (20). The stable LXA4 analogs 15R/S-methyl-
LXA4 and 16-phenoxy-LXA4 proved to be potent inhibi-
tors of IL-8 release induced by the high affinity (CD120b)
TNF-a receptor (Fig. 2), attenuating IL-8 release by as
much as 62 6 14% and 82 6 11%, respectively. Therefore,
these are the first results demonstrating that a lipid mediator
inhibits IL-8 release. These findings suggest a potentially
important new role for LXA4 as an endogenous “stop-sig-
nal” in the progression of an enterocyte-initiated inflam-
matory response.
COX II is expressed in human colonic tumors and ade-
nocarcinoma epithelial cell lines (for review see references
1 and 16) as well as in normal epithelial tissue in acute bac-
terial infections (19), mucosal lesions (17), and colitis (18).
Activation of this early response gene (e.g., COX II) is as-
sociated with both epithelial cell proliferation (for review
see reference 16) and wound healing, and selective inhibi-
tion of COX II exacerbates colon injury in several in vivo
Figure 6. Hypothetical scheme
of the antiinflammatory actions
of 15-epi-LXA4 and LXA4 stable
analogs in the alimentary tract.
Multistep recruitment of neutro-
phils to a site of mucosal inflam-
mation and enterocyte LXA4R
gene regulation by intraepithelial
lymphocyte-derived cytokines is
depicted. Activation of recep-
tors, present on both neutrophils
and enterocytes, inhibits PMN
migration to sites of inflamma-
tion. Targets or sites of action are
indicated by p for LXA4, aspirin-
triggered LXA4 (15-epi-LXA4),
and their stable analogs, which
include inhibition of PMN ad-
hesion to and transmigration
across both endothelia and epi-
thelia as well as inhibition of the
generation of a gradient of IL-8.
The biosynthesis of aspirin-trig-
gered 15-epi-LXA4 is illustrated
during PMN and enterocyte in-
teractions.1293 Gronert et al.
models (1, 17, 18). It is of interest to point out that the an-
alog 15R/S-methyl-LXA4, which inhibited enterocyte im-
mune function (Fig. 2), is a structurally related mimetic of
aspirin-triggered 15-epi-LXA4 (9). The observations that
cytokines upregulated enterocyte COX II and that these
cells (HT-29 Cl.19A) generate 15-HETE in the presence
of aspirin are in agreement with results reported with both
human vascular endothelial and lung epithelial cells (10,
11). Together, these in vitro findings suggest that, in sce-
narios where COX II is induced, enterocytes have the po-
tential in vivo to augment the biosynthesis of 15-epi-LXA4,
which may serve to inhibit further PMN accumulation
during mucosal inflammation (Fig. 6).
In summary, this is the first evidence demonstrating that
a cytokine regulates LXA4R expression in intestinal epithe-
lial cells, suggesting that the LXA4R is associated with en-
terocyte immune functions. In addition, our findings indicate
that LXA4 directly modulates the initiation of inflammatory
events by inhibiting the release of the potent chemokine
IL-8 at the initial site of pathogen exposure, namely at the
epithelial barrier. These results indicate that the potential
for antiinflammatory actions of LXA4 in the gastrointestinal
tract are multifaceted by acting on both myeloid cells to
counterregulate proinflammatory mediators (Fig. 6 and for
review see reference 9) and directly attenuating the initia-
tion of inflammation by modulating IL-8 release from epi-
thelia (Fig. 2). Thus, these findings with enterocytes and li-
poxins expand the bioactivity of these endogenous lipid
mediators and provide potential new uses for LXA4 stable
analogs in mucosal immunobiology.
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